Skip to main navigation

Investor Relations

January 23, 2019

Abivax Hosts KOL Event in Geneva on Therapeutic Candidate ABX464 for Ulcerative Colitis

December 20, 2018

Abivax’s phase 2a ulcerative colitis clinical trial data selected for oral plenary presentation at 14th Congress of European Crohn’s and Colitis Organisation

December 06, 2018

Abivax receives DSMB recommendation to continue ongoing extension study of its completed phase 2a clinical trial in ulcerative colitis patients

November 09, 2018

Abivax KOL event today in Paris on ABX464 therapeutic-candidate in mid-stage clinical testing for ulcerative colitis and HIV

September 28, 2018

Abivax First-Half 2018 Financial Results and Operations Update